Search

Your search keyword '"D. Laune"' showing total 20 results
Start Over Author "D. Laune" Topic rhinitis
20 results on '"D. Laune"'

1. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report.

Author

Bousquet J, Shamji MH, Anto JM, Schünemann HJ, Canonica GW, Jutel M, Del Giacco S, Zuberbier T, Pfaar O, Fonseca JA, Sousa-Pinto B, Klimek L, Czarlewski W, Bedbrook A, Amaral R, Ansotegui IJ, Bosnic-Anticevich S, Braido F, Chaves Loureiro C, Gemicioglu B, Haahtela T, Kulus M, Kuna P, Kupczyk M, Matricardi PM, Regateiro FS, Samolinski B, Sofiev M, Toppila-Salmi S, Valiulis A, Ventura MT, Barbara C, Bergmann KC, Bewick M, Blain H, Bonini M, Boulet LP, Bourret R, Brusselle G, Brussino L, Buhl R, Cardona V, Casale T, Cecchi L, Charpin D, Cherrez-Ojeda I, Chu DK, Cingi C, Costa EM, Cruz AA, Devillier P, Dramburg S, Fokkens WJ, Gotua M, Heffler E, Ispayeva Z, Ivancevich JC, Joos G, Kaidashev I, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Lourenço O, Louis R, Makela M, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, O'Hehir R, Okamoto Y, Olze H, Papadopoulos NG, Papi A, Patella V, Pétré B, Pham-Thi N, Puggioni F, Quirce S, Roche N, Rouadi PW, Sá-Sousa A, Sagara H, Sastre J, Scichilone N, Sheikh A, Sova M, Suppli Ulrik C, Taborda-Barata L, Todo-Bom A, Torres MJ, Tsiligianni I, Usmani OS, Valovirta E, Vasankari T, Vieira RJ, Wallace D, Waserman S, Zidarn M, Yorgancioglu A, Zhang L, Chivato T, and Ollert M

Subjects
Humans, Biomarkers, Patient-Centered Care, Rhinitis, Asthma diagnosis, Asthma therapy, Rhinitis, Allergic diagnosis, Rhinitis, Allergic therapy, Respiration Disorders
Abstract

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

2. Cutoff Values of MASK-air Patient-Reported Outcome Measures.

Author

Sousa-Pinto B, Sá-Sousa A, Vieira RJ, Amaral R, Pereira AM, Anto JM, Klimek L, Czarlewski W, Mullol J, Pfaar O, Bedbrook A, Brussino L, Kvedariene V, Larenas-Linnemann DE, Okamoto Y, Ventura MT, Ansotegui IJ, Bosnic-Anticevich S, Canonica GW, Cardona V, Cecchi L, Chivato T, Cingi C, Costa EM, Cruz AA, Del Giacco S, Devillier P, Fokkens WJ, Gemicioglu B, Haahtela T, Ivancevich JC, Kuna P, Kaidashev I, Kraxner H, Laune D, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Niedoszytko M, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sheikh A, Sova M, Taborda-Barata L, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Humans, Cross-Sectional Studies, Patient Reported Outcome Measures, Rhinitis, Allergic diagnosis, Rhinitis, Asthma epidemiology, Asthma therapy
Abstract

Background: In clinical and epidemiological studies, cutoffs of patient-reported outcome measures can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cutoffs in MASK-air have not been tested., Objective: To calculate cutoffs for VAS global, nasal, ocular, and asthma symptoms., Methods: In a cross-sectional study design of all MASK-air participants, we compared (1) approaches based on the percentiles (tertiles or quartiles) of VAS distributions and (2) data-driven approaches based on clusters of data from 2 comparators (VAS work and VAS sleep). We then performed sensitivity analyses for individual countries and for VAS levels corresponding to full allergy control. Finally, we tested the different approaches using MASK-air real-world cross-sectional and longitudinal data to assess the most relevant cutoffs., Results: We assessed 395,223 days from 23,201 MASK-air users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cutoff values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cutoff differentiating "controlled" and "partly-controlled" patients was similar to the cutoff value that had been arbitrarily used (20/100). However, a lower cutoff was obtained to differentiate between "partly-controlled" and "uncontrolled" patients (35 vs the arbitrarily-used value of 50/100)., Conclusions: Using a data-driven approach, we were able to define cutoff values for MASK-air VASs on allergy and asthma symptoms. This may allow for a better classification of patients with rhinitis and asthma according to different levels of control, supporting improved disease management., (Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

3. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

Author

Sousa-Pinto B, Schünemann HJ, Sá-Sousa A, Vieira RJ, Amaral R, Anto JM, Klimek L, Czarlewski W, Mullol J, Pfaar O, Bedbrook A, Brussino L, Kvedariene V, Larenas-Linnemann DE, Okamoto Y, Ventura MT, Agache I, Ansotegui IJ, Bergmann KC, Bosnic-Anticevich S, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, Del Giacco S, Devillier P, Eklund P, Fokkens WJ, Gemicioglu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Khaitov M, Kraxner H, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Niedoszytko M, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sheikh A, Sova M, Todo-Bom A, Taborda-Barata L, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Humans, Longitudinal Studies, Surveys and Questionnaires, Rhinitis epidemiology, Telemedicine
Abstract

Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air® longitudinally, clustering weeks according to reported rhinitis symptoms., Methods: We analyzed MASK-air® data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results., Results: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age ± SD = 39.1 ± 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control., Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

4. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.

Author

Sousa-Pinto B, Schünemann HJ, Sá-Sousa A, Vieira RJ, Amaral R, Anto JM, Klimek L, Czarlewski W, Mullol J, Pfaar O, Bedbrook A, Brussino L, Kvedariene V, Larenas-Linnemann D, Okamoto Y, Ventura MT, Agache I, Ansotegui IJ, Bergmann KC, Bosnic-Anticevich S, Brozek J, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, Del Giacco S, Devillier P, Eklund P, Fokkens WJ, Gemicioglu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Khaitov M, Kraxner H, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Niedoszytko M, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sheikh A, Sova M, Todo-Bom A, Taborda-Barata L, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Adrenal Cortex Hormones therapeutic use, Desensitization, Immunologic, Fluticasone therapeutic use, Humans, Rhinitis drug therapy, Rhinitis, Allergic therapy
Abstract

Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT., Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication., Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80)., Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines., (© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

5. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air ® real-world data.

Author

Sousa-Pinto B, Sá-Sousa A, Vieira RJ, Amaral R, Klimek L, Czarlewski W, Antó JM, Pfaar O, Bedbrook A, Kvedariene V, Ventura MT, Ansotegui IJ, Bergmann KC, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, De Feo G, Devillier P, Fokkens WJ, Gaga M, Gemicioğlu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Kraxner H, Larenas-Linnemann DE, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Mullol J, Odemyr M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sova M, Todo-Bom A, Taborda-Barata L, Tomazic PV, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Europe epidemiology, Habits, Histamine Antagonists therapeutic use, Humans, Rhinitis drug therapy, Rhinitis, Allergic drug therapy, Rhinitis, Allergic epidemiology
Abstract

Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data., Methods: We analysed 2015-2020 MASK-air ® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year., Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H 1 -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more., Conclusions: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

6. Development and validation of combined symptom-medication scores for allergic rhinitis.

Author

Sousa-Pinto B, Azevedo LF, Jutel M, Agache I, Canonica GW, Czarlewski W, Papadopoulos NG, Bergmann KC, Devillier P, Laune D, Klimek L, Anto A, Anto JM, Eklund P, Almeida R, Bedbrook A, Bosnic-Anticevich S, Brough HA, Brussino L, Cardona V, Casale T, Cecchi L, Charpin D, Chivato T, Costa EM, Cruz AA, Dramburg S, Durham SR, De Feo G, Gerth van Wijk R, Fokkens WJ, Gemicioglu B, Haahtela T, Illario M, Ivancevich JC, Kvedariene V, Kuna P, Larenas-Linnemann DE, Makris M, Mathieu-Dupas E, Melén E, Morais-Almeida M, Mösges R, Mullol J, Nadeau KC, Pham-Thi N, O'Hehir R, Regateiro FS, Reitsma S, Samolinski B, Sheikh A, Stellato C, Todo-Bom A, Tomazic PV, Toppila-Salmi S, Valero A, Valiulis A, Ventura MT, Wallace D, Waserman S, Yorgancioglu A, De Vries G, van Eerd M, Zieglmayer P, Zuberbier T, Pfaar O, Almeida Fonseca J, and Bousquet J

Subjects
Humans, Quality of Life, Reproducibility of Results, Asthma drug therapy, Rhinitis, Rhinitis, Allergic diagnosis, Rhinitis, Allergic drug therapy
Abstract

Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air ® app to generate and validate hypothesis- and data-driven CSMSs., Methods: We used MASK-air ® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air ® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air ® , and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT])., Results: We assessed 317,176 days of MASK-air ® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820)., Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

7. A demonstration project of Global Alliance against Chronic Respiratory Diseases: Prediction of interactions between air pollution and allergen exposure-the Mobile Airways Sentinel NetworK-Impact of air POLLution on Asthma and Rhinitis approach.

Author

Sofiev M, Palamarchuk Y, Bédard A, Basagana X, Anto JM, Kouznetsov R, Urzua RD, Bergmann KC, Fonseca JA, De Vries G, Van Erd M, Annesi-Maesano I, Laune D, Pépin JL, Jullian-Desayes I, Zeng S, Czarlewski W, and Bousquet J

Subjects
Allergens, Humans, Air Pollution adverse effects, Asthma etiology, Rhinitis, Rhinitis, Allergic, Seasonal
Abstract

This review analyzes the state and recent progress in the field of information support for pollen allergy sufferers. For decades, information available for the patients and allergologists consisted of pollen counts, which are vital but insufficient. New technology paves the way to substantial increase in amount and diversity of the data. This paper reviews old and newly suggested methods to predict pollen and air pollutant concentrations in the air and proposes an allergy risk concept, which combines the pollen and pollution information and transforms it into a qualitative risk index. This new index is available in an app (Mobile Airways Sentinel NetworK-air) that was developed in the frame of the European Union grant Impact of Air POLLution on sleep, Asthma and Rhinitis (a project of European Institute of Innovation and Technology-Health). On-going transformation of the pollen allergy information support is based on new technological solutions for pollen and air quality monitoring and predictions. The new information-technology and artificial-intelligence-based solutions help to convert this information into easy-to-use services for both medical practitioners and allergy sufferers.

Published
2020
Full Text
View/download PDF

8. Interactions Between Air Pollution and Pollen Season for Rhinitis Using Mobile Technology: A MASK-POLLAR Study.

Author

Bédard A, Sofiev M, Arnavielhe S, Antó JM, Garcia-Aymerich J, Thibaudon M, Bergmann KC, Dubakiene R, Bedbrook A, Onorato GL, Annesi-Maesano I, Pépin JL, Laune D, Zeng S, Bousquet J, and Basagaña X

Subjects
Europe, Humans, Pollen, Seasons, Air Pollutants adverse effects, Air Pollution adverse effects, Rhinitis, Rhinitis, Allergic, Seasonal epidemiology
Abstract

Background: Several studies have suggested an interaction between air pollution and pollen exposure with an impact on allergy symptoms. However, large studies with real-life data are not available., Objective: To investigate associations between major air pollutants (ozone and particulate matter with a diameter of <2.5 μm) and allergic rhinitis (AR) control during grass and birch pollen seasons as well as outside the pollen season., Methods: The daily impact of allergic symptoms was recorded by the Allergy Diary (Mobile Airways Sentinel NetworK [MASK-air]) app (a validated mHealth tool for rhinitis management) using visual analog scales (VASs) in Northern and Central Europe users in 2017 and 2018. Uncontrolled AR was defined using symptoms and medications. Pollutant levels were assessed using the System for Integrated modeLing of Atmospheric coMposition database. Pollen seasons were assessed by regions using Google Trends. Generalized estimating equation models were used to account for repeated measures per user, adjusting for sex, age, treatment, and country. Analyses were stratified by pollen seasons to investigate interactions between air pollutants and pollen exposure., Results: A total of 3323 geolocated individuals (36,440 VAS-days) were studied. Associations between uncontrolled rhinitis and pollutants were stronger during the grass pollen season. Days with uncontrolled AR increased by 25% for an interquartile range increase in ozone levels during the grass pollen season (odds ratio of 1.25 [95% CI, 1.11-1.41] in 2017 and of 1.14 [95% CI, 1.04-1.25] in 2018). A similar trend was found for particulate matter with a diameter of less than 2.5 μm, especially in 2017., Conclusions: These results suggest that the relationship between uncontrolled AR and air pollution is modified by the presence of grass pollens. This study confirms the impact of pollutants in the grass pollen season but not in the birch pollen season., (Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

9. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study.

Author

Bousquet J, Devillier P, Anto JM, Bewick M, Haahtela T, Arnavielhe S, Bedbrook A, Murray R, van Eerd M, Fonseca JA, Morais Almeida M, Todo Bom A, Menditto E, Passalacqua G, Stellato C, Triggiani M, Ventura MT, Vezzani G, Annesi-Maesano I, Bourret R, Bosse I, Caimmi D, Cartier C, Demoly P, Just J, Portejoie F, Siroux V, Viart F, Bergmann KC, Keil T, Klimek L, Mösges R, Pfaar O, Shamai S, Zuberbier T, Mullol J, Valero A, Spranger O, Tomazic PV, Kowalski ML, Kuna P, Kupczyk M, Raciborski F, Samolinski B, Toppila-Salmi SK, Valovirta E, Cruz AA, Sarquis-Serpa F, da Silva J, Stelmach R, Larenas-Linnemann D, Rodriguez Gonzalez M, Burguete Cabañas MT, Kvedariene V, Valiulis A, Chavannes NH, Fokkens WJ, Ryan D, Sheikh A, Bachert C, Hellings PW, VandenPlas O, Ballardini N, Kull I, Melén E, Westman M, Wickman M, Bindslev-Jensen C, Eller E, Bosnic-Anticevich S, O'Hehir RE, Agache I, Bieber T, Casale T, Gemicioğlu B, Ivancevich JC, De Vries G, Sorensen M, Yorgancioglu A, and Laune D

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Male, Middle Aged, Patient Outcome Assessment, Prevalence, Prospective Studies, Research Design, Young Adult, Hypersensitivity epidemiology, Mobile Applications, Multimorbidity, Rhinitis epidemiology
Abstract

Background: Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary., Methods: We undertook a 1-year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels <20/100 were categorized as "Low" burden and VAS levels ≥50/100 as "High" burden., Results: Visual analogue scales global measured levels assessing the global control of the allergic disease were significantly associated with allergic multimorbidity. Eight hypothesis-driven patterns were defined based on "Low" and "High" VAS levels. There were <0.2% days of Rhinitis Low and Asthma High or Conjunctivitis High patterns. There were 5.9% days with a Rhinitis High-Asthma Low pattern. There were 1.7% days with a Rhinitis High-Asthma High-Conjunctivitis Low pattern. A novel Rhinitis High-Asthma High-Conjunctivitis High pattern was identified in 2.9% days and had the greatest impact on uncontrolled VAS global measured and impaired work productivity. Work productivity was significantly correlated with VAS global measured levels., Conclusions: In a novel approach examining daily symptoms with mobile technology, we found considerable intra-individual variability of allergic multimorbidity including a previously unrecognized extreme pattern of uncontrolled multimorbidity., (© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Published
2018
Full Text
View/download PDF

10. Work productivity in rhinitis using cell phones: The MASK pilot study.

Author

Bousquet J, Bewick M, Arnavielhe S, Mathieu-Dupas E, Murray R, Bedbrook A, Caimmi DP, Vandenplas O, Hellings PW, Bachert C, Anto JM, Bergmann KC, Bindslev-Jensen C, Bosnic-Anticevich S, Bouchard J, Canonica GW, Chavannes NH, Cruz AA, Dahl R, Demoly P, De Vries G, Devillier P, Fink-Wagner A, Fokkens WJ, Fonseca J, Guldemond NA, Haahtela T, Hellqvist-Dahl B, Just J, Keil T, Klimek L, Kowalski ML, Kuna P, Kvedariene V, Laune D, Larenas-Linnemann D, Mullol J, Pereira AM, Carreiro-Martins P, Melén E, Morais-Almeida M, Nogueira-Silva L, O'Hehir RE, Papadopoulos NG, Passalacqua G, Portejoie F, Price D, Ryan D, Samolinski B, Sheikh A, Simons FER, Spranger O, Todo Bom A, Tomazic PV, Triggiani M, Valero A, Valovirta E, Valiulis A, van Eerd M, Wickman M, Young I, and Zuberbier T

Subjects
Humans, Pilot Projects, Public Health Surveillance, Rhinitis diagnosis, Severity of Illness Index, Surveys and Questionnaires, Symptom Assessment, Cell Phone, Efficiency, Rhinitis epidemiology, Work Performance
Abstract

Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to use cell phone data to assess the impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS). A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work). A combined nasal-ocular score is calculated. The Allergy Diary is available in 21 countries. The app includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) in six EU countries. All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in the study. A total of 1136 users filled in 5818 days of VAS-work. Symptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days. In users with uncontrolled rhinitis, approximately 90% had some work impairment and over 50% had severe work impairment (VAS-work >50). There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test). In 144 users, there was a significant correlation between VAS-work and WPAI:AS (Rho=0.53, P<0.0001). This pilot study provides not only proof-of-concept data on the work impairment collected with the app but also data on the app itself, especially the distribution of responses for the VAS. This supports the interpretation that persons with rhinitis report both the presence and the absence of symptoms., (© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Published
2017
Full Text
View/download PDF

11. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

Author

J. Bousquet, A. Bedbrook, W. Czarlewski, G. L. Onorato, S. Arnavielhe, D. Laune, E. Mathieu-Dupas, J. Fonseca, E. Costa, O. Lourenço, M. Morais-Almeida, A. Todo-Bom, M. Illario, E. Menditto, G. W. Canonica, L. Cecchi, R. Monti, L. Napoli, M. T. Ventura, G. De Feo, W. J. Fokkens, N. H. Chavannes, S. Reitsma, A. A. Cruz, J. da Silva, F. S. Serpa, D. Larenas-Linnemann, J. M. Fuentes Perez, Y. R. Huerta-Villalobos, D. Rivero-Yeverino, E. Rodriguez-Zagal, A. Valiulis, R. Dubakiene, R. Emuzyte, V. Kvedariene, I. Annesi-Maesano, H. Blain, P. Bonniaud, I. Bosse, Y. Dauvilliers, P. Devillier, J. F. Fontaine, J. L. Pépin, N. Pham-Thi, F. Portejoie, R. Picard, N. Roche, C. Rolland, P. Schmidt-Grendelmeier, P. Kuna, B. Samolinski, J. M. Anto, V. Cardona, J. Mullol, H. Pinnock, D. Ryan, A. Sheikh, S. Walker, S. Williams, S. Becker, L. Klimek, O. Pfaar, K. C. Bergmann, R. Mösges, T. Zuberbier, R. E. Roller-Wirnsberger, P. V. Tomazic, T. Haahtela, J. Salimäki, S. Toppila-Salmi, E. Valovirta, T. Vasankari, B. Gemicioğlu, A. Yorgancioglu, N. G. Papadopoulos, E. P. Prokopakis, I. G. Tsiligianni, S. Bosnic-Anticevich, R. O’Hehir, J. C. Ivancevich, H. Neffen, M. E. Zernotti, I. Kull, E. Melén, M. Wickman, C. Bachert, P. W. Hellings, G. Brusselle, S. Palkonen, C. Bindslev-Jensen, E. Eller, S. Waserman, L. P. Boulet, J. Bouchard, D. K. Chu, H. J. Schünemann, M. Sova, G. De Vries, M. van Eerd, I. Agache, I. J. Ansotegui, M. Bewick, T. Casale, M. Dykewick, M. Ebisawa, R. Murray, R. Naclerio, Y. Okamoto, D. V. Wallace, and The MASK study group

Subjects
App, Asthma, Care pathways, MASK, mHealth, Rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Aims Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors. Results MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018) MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.

Published
2019
Full Text
View/download PDF

12. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

Author

D. Samreth, S. Arnavielhe, F. Ingenrieth, A. Bedbrook, G. L. Onorato, R. Murray, R. Almeida, M. A. Mizani, J. Fonseca, E. Costa, J. Malva, M. Morais-Almeida, A. M. Pereira, A. Todo-Bom, E. Menditto, C. Stellato, M. T. Ventura, D. Larenas-Linnemann, J-M. Fuentes-Pérez, Y. R. Huerta-Villalobos, A. A. Cruz, R. Stelmach, J. da Silva, R. Emuzyte, V. Kvedariene, A. Valiulis, I. Annesi-Maesano, I. Bosse, P. Demoly, P. Devillier, J. F. Fontaine, P. Kuna, B. Samolinski, L. Klimek, R. Mösges, O. Pfaar, S. Shamai, M. Bewick, D. Ryan, A. Sheikh, J. M. Anto, V. Cardona, J. Mullol, A. Valero, N. H. Chavannes, W. J. Fokkens, S. Reitsma, R. E. Roller-Wirnsberger, P. V. Tomazic, T. Haahtela, S. Toppila-Salmi, E. Valovirta, M. Makris, N. G. Papadopoulos, E. P. Prokopakis, F. Psarros, B. Gemicioğlu, A. Yorgancioglu, C. Bindslev-Jensen, E. Eller, I. Kull, M. Wickman, C. Bachert, P. W. Hellings, B. Pugin, S. Bosnic-Anticevich, R. E. O’Hehir, V. Kolek, M. Sova, K. Wehner, G. De Vries, M. van Eerd, D. Laune, J. Wittmann, J. Bousquet, P. Poncelet, and the MASK study group

Subjects
Anonymization, App, MASK, Rhinitis, Asthma, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission’s Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58.5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users’ life privacy. Discussion k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases.

Published
2018
Full Text
View/download PDF

13. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

J. Bousquet, G. L. Onorato, C. Bachert, M. Barbolini, A. Bedbrook, L. Bjermer, J. Correia de Sousa, N. H. Chavannes, A. A. Cruz, E. De Manuel Keenoy, P. Devillier, J. Fonseca, S. Hun, T. Kostka, P. W. Hellings, M. Illario, J. C. Ivancevich, D. Larenas-Linnemann, J. Millot-Keurinck, D. Ryan, B. Samolinski, A. Sheikh, A. Yorgancioglu, I. Agache, S. Arnavielhe, M. Bewick, I. Annesi-Maesano, J. M. Anto, K. C. Bergmann, C. Bindslev-Jensen, S. Bosnic-Anticevich, J. Bouchard, D. P. Caimmi, P. Camargos, G. W. Canonica, V. Cardona, A. M. Carriazo, C. Cingi, E. Colgan, A. Custovic, R. Dahl, P. Demoly, G. De Vries, W. J. Fokkens, J. F. Fontaine, B. Gemicioğlu, N. Guldemond, Z. Gutter, T. Haahtela, B. Hellqvist-Dahl, E. Jares, G. Joos, J. Just, N. Khaltaev, T. Keil, L. Klimek, M. L. Kowalski, I. Kull, P. Kuna, V. Kvedariene, D. Laune, R. Louis, A. Magnan, J. Malva, E. Mathieu-Dupas, E. Melén, E. Menditto, M. Morais-Almeida, R. Mösges, J. Mullol, R. Murray, H. Neffen, R. O’Hehir, S. Palkonen, N. G. Papadopoulos, G. Passalacqua, J. L. Pépin, F. Portejoie, D. Price, B. Pugin, F. Raciborski, F. E. R. Simons, M. Sova, O. Spranger, C. Stellato, A. Todo Bom, P. V. Tomazic, M. Triggiani, A. Valero, E. Valovirta, O. VandenPlas, A. Valiulis, M. van Eerd, M. T. Ventura, M. Wickman, I. Young, T. Zuberbier, A. Zurkuhlen, and A. Senn

Subjects
Rhinitis, Asthma, CHRODIS, ARIA, MASK, Sunfrail, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.

Published
2017
Full Text
View/download PDF

14. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

Author

J. Bousquet, B. Sousa-Pinto, J.M. Anto, R. Amaral, L. Brussino, G.W. Canonica, A.A. Cruz, B. Gemicioglu, T. Haahtela, M. Kupczyk, V. Kvedariene, D.E. Larenas-Linnemann, R. Louis, N. Pham-Thi, F. Puggioni, F.S. Regateiro, J. Romantowski, J. Sastre, N. Scichilone, L. Taborda-Barata, M.T. Ventura, I. Agache, A. Bedbrook, K.C. Bergmann, S. Bosnic-Anticevich, M. Bonini, L.-P. Boulet, G. Brusselle, R. Buhl, L. Cecchi, D. Charpin, C. Chaves-Loureiro, W. Czarlewski, F. de Blay, P. Devillier, G. Joos, M. Jutel, L. Klimek, P. Kuna, D. Laune, J.L. Pech, M. Makela, M. Morais-Almeida, R. Nadif, M. Niedoszytko, K. Ohta, N.G. Papadopoulos, A. Papi, D.R. Yeverino, N. Roche, A. Sá-Sousa, B. Samolinski, M.H. Shamji, A. Sheikh, C. Suppli Ulrik, O.S. Usmani, A. Valiulis, O. Vandenplas, A. Yorgancioglu, T. Zuberbier, J.A. Fonseca, Publica, Bousquet, Jean, Antó i Boqué, Josep Maria, Fonseca, Joao A., UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie

Subjects
Pulmonary and Respiratory Medicine, treatment, Socio-culturale, Asthma, cluster analysis, control, rhinitis, treatment, Asthma, Cluster analysis, Control, Rhinitis, Treatment, rhinitis, control, cluster analysis
Abstract

Data de publicació electrònica: 22-11-2022 Background: The self-reporting of asthma frequently leads to patient misidentification in epidemiological studies. Strategies combining the triangulation of data sources may help to improve the identification of people with asthma. We aimed to combine information from the self-reporting of asthma, medication use and symptoms to identify asthma patterns in the users of an mHealth app. Methods: We studied MASK-air® users who reported their daily asthma symptoms (assessed by a 0-100 visual analogue scale - "VAS Asthma") at least three times (either in three different months or in any period). K-means cluster analysis methods were applied to identify asthma patterns based on: (i) whether the user self-reported asthma; (ii) whether the user reported asthma medication use and (iii) VAS asthma. Clusters were compared by the number of medications used, VAS asthma levels and Control of Asthma and Allergic Rhinitis Test (CARAT) levels. Findings: We assessed a total of 8,075 MASK-air® users. The main clustering approach resulted in the identification of seven groups. These groups were interpreted as probable: (i) severe/uncontrolled asthma despite treatment (11.9-16.1% of MASK-air® users); (ii) treated and partly-controlled asthma (6.3-9.7%); (iii) treated and controlled asthma (4.6-5.5%); (iv) untreated uncontrolled asthma (18.2-20.5%); (v) untreated partly-controlled asthma (10.1-10.7%); (vi) untreated controlled asthma (6.7-8.5%) and (vii) no evidence of asthma (33.0-40.2%). This classification was validated in a study of 192 patients enrolled by physicians. Interpretation: We identified seven profiles based on the probability of having asthma and on its level of control. mHealth tools are hypothesis-generating and complement classical epidemiological approaches in identifying patients with asthma.

Published
2023

15. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

Author

Bernardo Sousa-Pinto, Ana Sá-Sousa, Rita Amaral, Wienczyslawa Czarlewski, Anna Bedbrook, Josep M. Anto, Jean Bousquet, João Almeida Fonseca, I. Agache, X. Basagaña, A. Bédard, K.C. Bergmann, C. Bindslev-Jensen, H. Blain, S. Bosnic-Anticevich, I. Bosse, L.P. Boulet, L. Brussino, P. Camargos, G.W. Canonica, P. Carreiro-Martins, V. Cardona, L. Cecchi, D. Chu, E. Costa, A.A. Cruz, J. da Silva, G. De Vries, P. Devillier, W.J. Fokkens, J.F. Fontaine, J.-M. Fuentes-Pérez, B. Gemicioğlu, T. Haahtela, Y.R. Huerta-Villalobos, J.C. Ivancevich, M. Jutel, I. Kaidashev, M. Khaitov, L. Klimek, H. Kraxner, P. Kuna, V. Kvedariene, D.E.S. Larenas-Linnemann, D. Laune, B. Lipworth, P. Manning, M. Makris, E. Melén, M. Morais-Almeida, R. Mösges, J. Mullol, K. Nekam, M. Niedoszytko, R.E. O'Hehir, Y. Okamoto, N.G. Papadopoulos, V. Patella, O. Pfaar, N. Pham-Thi, F.S. Regateiro, S. Reitsma, P.W. Rouadi, B. Samolinski, F. Sarquis-Serpa, J. Sastre, N. Scichilone, R. Stelmach, C. Suppli-Ulrik, A. Todo-Bom, P.V. Tomazic, S. Toppila-Salmi, I. Tsigiliani, A. Valero, A. Valiulis, E. Valovirta, M. van Eerd, M.T. Ventura, S. Waserman, A. Yorgancioglu, M. Zidarn, Sousa-Pinto B., Sa-Sousa A., Amaral R., Czarlewski W., Bedbrook A., Anto J.M., Bousquet J., Fonseca J.A., Agache I., Basagana X., Bedard A., Bergmann K.C., Bindslev-Jensen C., Blain H., Bosnic-Anticevich S., Bosse I., Boulet L.P., Brussino L., Camargos P., Canonica G.W., Carreiro-Martins P., Cardona V., Cecchi L., Chu D., Costa E., Cruz A.A., da Silva J., De Vries G., Devillier P., Fokkens W.J., Fontaine J.F., Fuentes-Perez J.-M., Gemicioglu B., Haahtela T., Huerta-Villalobos Y.R., Ivancevich J.C., Jutel M., Kaidashev I., Khaitov M., Klimek L., Kraxner H., Kuna P., Kvedariene V., Larenas-Linnemann D.E.S., Laune D., Lipworth B., Manning P., Makris M., Melen E., Morais-Almeida M., Mosges R., Mullol J., Nekam K., Niedoszytko M., O'Hehir R.E., Okamoto Y., Papadopoulos N.G., Patella V., Pfaar O., Pham-Thi N., Regateiro F.S., Reitsma S., Rouadi P.W., Samolinski B., Sarquis-Serpa F., Sastre J., Scichilone N., Stelmach R., Suppli-Ulrik C., Todo-Bom A., Tomazic P.V., Toppila-Salmi S., Tsigiliani I., Valero A., Valiulis A., Valovirta E., van Eerd M., Ventura M.T., Waserman S., Yorgancioglu A., Zidarn M., Ear, Nose and Throat, and AII - Inflammatory diseases

Subjects
Carat, medicine.medical_specialty, business.industry, MEDLINE, Settore MED/10 - Malattie Dell'Apparato Respiratorio, medicine.disease, Rhinitis, Allergic, Asthma, Test (assessment), Internal medicine, Humans, Immunology and Allergy, Medicine, business, Rhinitis
Abstract

n/a

Published
2022

16. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study

Author

Olivier Vandenplas, R. Murray, Niels H. Chavannes, Erkka Valovirta, A. Fink-Wagner, Alvaro A. Cruz, Joaquim Mullol, Aziz Sheikh, G. De Vries, T. Keil, M. Wickman, K. C. Bergmann, Pascal Demoly, Dermot Ryan, Nick A. Guldemond, Torsten Zuberbier, V. Kvedariene, Luís Nogueira-Silva, Mikael Kuitunen, A. Valiulis, G. Passalacqua, Claus Bachert, Davide Caimmi, Antonella Muraro, E Mathieu-Dupas, João Fonseca, P V Tomazic, Jean Bousquet, P. Devillier, S. Arnavielhe, Pedro Carreiro-Martins, Erik Melén, Giorgio Walter Canonica, D. Laune, Nikolaos G. Papadopoulos, M. Bewick, Ronald Dahl, A. Valero, B. Hellqvist-Dahl, Peter Hellings, B. Samolinski, L. Klimek, S. van der Meulen, J. Just, M. Morais-Almeida, David Price, Tari Haahtela, O. Spranger, A. Todo Bom, Ana Margarida Pereira, M. van Eerd, F. Portejoie, M. L. Kowalski, A. Bedbrook, Piotr Kuna, Valérie Siroux, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon ( MACVIA-LR ), Université Montpellier 1 ( UM1 ) -World Health Organization ( WHO/OMS ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ) -European Innovation Partnership on Active and Healthy Ageing Reference Site, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique ( VIMA ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Hôpital Foch [Suresnes], Department of Dermatology, Medical School-Charité - University Medicine Berlin, Forschungszentrum Jülich GmbH - Projektträger BEO, GmbH, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Universidade de Lisboa ( ULISBOA ), Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], Institut de Recherche en Infectiologie de Montpellier ( IRIM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Allergy Department, 2nd Pediatric Clinic, Allergy & Respiratory Diseases, University of Genoa ( UNIGE ) -Department of Internal Medicine (DIMI), Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw-Faculté de Pharmacie de Paris, Center for Public Health Research ( CSISP ), University of Valencia, CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, Department of Molecular Medicine and Surgery, Karolinska Institutet [Stockholm], Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Universidade de Lisboa = University of Lisbon (ULISBOA), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Università degli studi di Genova = University of Genoa (UniGe)-Department of Internal Medicine (DIMI), Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Center for Public Health Research (CSISP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade de Lisboa (ULISBOA), Service d'Allergologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Department of Internal Medicine (DIMI)-University of Genoa (UNIGE), Health Services Management & Organisation (HSMO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and University of Genoa (UNIGE)-Department of Internal Medicine (DIMI)

Subjects
0301 basic medicine, EIP on AHA, Pediatrics, medicine.medical_specialty, Allergen immunotherapy, Pathology, Allergy, [SDV]Life Sciences [q-bio], Immunology, Pilot Projects, Review, Asymptomatic, 03 medical and health sciences, Allergic, 0302 clinical medicine, HDE ALER, Surveys and Questionnaires, Journal Article, medicine, Humans, Immunology and Allergy, Rhinitis, Asthma, Allergy Diary, rhinorrhea, [ SDV ] Life Sciences [q-bio], business.industry, Research, MASK-rhinitis, Baseline data, Conjunctivitis, medicine.disease, Rhinitis, Allergic, Mobile Applications, 3. Good health, Europe, Mobile technology, mobile technology, 030104 developmental biology, 030228 respiratory system, Baseline characteristics, allergen immunotherapy, medicine.symptom, business, Cell Phone, Nasal symptoms
Abstract

The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). AIMS: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. METHODS: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. RESULTS: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. CONCLUSIONS: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods info:eu-repo/semantics/publishedVersion

Published
2017

17. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study

Author

Ralph Mösges, T. Keil, Davide Caimmi, N. Ballardini, Thomas B. Casale, M. Morais Almeida, M. Rodriguez Gonzalez, Massimo Triggiani, Erik Melén, M. Wickman, Filip Raciborski, Sinthia Bosnic-Anticevich, P. V. Tomazic, Rafael Stelmach, Pascal Demoly, W. J. Fokkens, A. Bedbrook, Maciej Kupczyk, Jean Bousquet, K. C. Bergmann, A. Valero, M. T. Burguete Cabañas, Valérie Siroux, I. Annesi-Maesano, Torsten Zuberbier, Sanna Toppila-Salmi, Juan Carlos Ivancevich, A. Valiulis, Olivier Vandenplas, Ioana Agache, Frederic Viart, F. Portejoie, Cristiana Stellato, Josep M. Antó, D. Laune, V. Kvedariene, D. Larenas-Linnemann, J. da Silva, Ruth Murray, Piotr Kuna, Esben Eller, F. Sarquis-Serpa, Isabelle Bosse, Claus Bachert, P. Devillier, R. Bourret, M. L. Kowalski, Bilun Gemicioglu, Erkka Valovirta, Alvaro A. Cruz, M. Bewick, Tari Haahtela, O. Spranger, A. Yorgancioglu, Enrica Menditto, Aziz Sheikh, G. De Vries, Marit Westman, Oliver Pfaar, S. Arnavielhe, C. Cartier, G. Passalacqua, Dermot Ryan, S. Shamai, B. Samolinski, A. Todo Bom, Martin Sørensen, Inger Kull, M. van Eerd, Carsten Bindslev-Jensen, Niels H. Chavannes, Joaquim Mullol, T. Bieber, João Fonseca, G. Vezzani, Robyn E O'Hehir, Peter Hellings, M. T. Ventura, L. Klimek, J. Just, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Foch [Suresnes], University of Helsinki, 'Federico II' University of Naples Medical School, Département Chirurgie Pédiatrique [CHRU Montpellier], Pôle Femme Mère Enfant [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Heidelberg University, University of Barcelona, Karl-Franzens-Universität [Graz, Autriche], University of Turku, Vilnius University [Vilnius], University of Edinburgh, Ghent University Hospital, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], The University of Sydney, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J., Devillier, P., Anto, J. M., Bewick, M., Haahtela, T., Arnavielhe, S., Bedbrook, A., Murray, R., van Eerd, M., Fonseca, J. A., Morais Almeida, M., Todo Bom, A., Menditto, E., Passalacqua, G., Stellato, C., Triggiani, M., Ventura, M. T., Vezzani, G., Annesi-Maesano, I., Bourret, R., Bosse, I., Caimmi, D., Cartier, C., Demoly, P., Just, J., Portejoie, F., Siroux, V., Viart, F., Bergmann, K. C., Keil, T., Klimek, L., Mosges, R., Pfaar, O., Shamai, S., Zuberbier, T., Mullol, J., Valero, A., Spranger, O., Tomazic, P. V., Kowalski, M. L., Kuna, P., Kupczyk, M., Raciborski, F., Samolinski, B., Toppila-Salmi, S. K., Valovirta, E., Cruz, A. A., Sarquis-Serpa, F., da Silva, J., Stelmach, R., Larenas-Linnemann, D., Rodriguez Gonzalez, M., Burguete Cabanas, M. T., Kvedariene, V., Valiulis, A., Chavannes, N. H., Fokkens, W. J., Ryan, D., Sheikh, A., Bachert, C., Hellings, P. W., Vandenplas, O., Ballardini, N., Kull, I., Melen, E., Westman, M., Wickman, M., Bindslev-Jensen, C., Eller, E., Bosnic-Anticevich, S., O'Hehir, R. E., Agache, I., Bieber, T., Casale, T., Gemicioglu, B., Ivancevich, J. C., De Vries, G., Sorensen, M., Yorgancioglu, A., and Laune, D.

Subjects
Male, Allergy, SYMPTOMS, IMPACT, CHILDREN, WORLD-HEALTH-ORGANIZATION, Review, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, QUALITY-OF-LIFE, conjunctiviti, Prevalence, conjunctivitis, Immunology and Allergy, Prospective Studies, Young adult, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Child, Prospective cohort study, asthma, multimorbidit, rhinitis, work productivity, Nose, Aged, 80 and over, Respiratory organs diseases, Middle Aged, Mobile Applications, 3. Good health, rhiniti, medicine.anatomical_structure, Research Design, MEDALL, GA(2)LEN, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Life Sciences & Biomedicine, Human, Adult, medicine.medical_specialty, Adolescent, multimorbidity, Visual analogue scale, Mobile Application, Immunology, MECHANISMS, Malalties de l'aparell respiratori, Young Adult, 03 medical and health sciences, Internal medicine, Hypersensitivity, medicine, Journal Article, Humans, asthma, conjunctivitis, multimorbidity, rhinitis, work productivity, Aged, Asthma, Science & Technology, business.industry, medicine.disease, Patient Outcome Assessment, Prospective Studie, Morbiditat, 030228 respiratory system, Observational study, Rhinithis, VISUAL ANALOG SCALE, Morbidity, business
Abstract

BACKGROUND: Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary. METHODS: We undertook a 1-year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels

Published
2018

18. Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study

Author

Valérie Siroux, Cristiana Stellato, Olivier Vandenplas, Isabella Annesi-Maesano, P V Tomazic, A. Bedbrook, Luís Nogueira-Silva, M. Morais Almeida, Maddalena Illario, Wytske J. Fokkens, Piotr Kuna, Isabelle Bosse, Erik Melén, Joaquim Mullol, G Alexis-Alexandre, Esben Eller, Nikolaos G. Papadopoulos, Pascal Demoly, B. Samolinski, D. Larenas-Linnemann, Carsten Bindslev-Jensen, Peter McDowall, Ana Margarida Pereira, M. Bewick, Josep M. Antó, Torsten Zuberbier, A. Todo Bom, Pedro Carreiro-Martins, R. Murray, A. Yorgancioglu, F. Portejoie, Robyn E O'Hehir, E Murphy, Inger Kull, D. Laune, A. Valiulis, G. Passalacqua, T. Keil, Peter Hellings, M. L. Kowalski, Bilun Gemicioglu, Alvaro A. Cruz, P. Devillier, A. Valero, L. Klimek, Aziz Sheikh, G. De Vries, J. Just, Davide Caimmi, Niels H. Chavannes, K. C. Bergmann, João Fonseca, Erkka Valovirta, J. F. Fontaine, Dermot Ryan, S. Shamai, Massimo Triggiani, Enrica Menditto, Giorgio Walter Canonica, M. Wickman, Jean Bousquet, Sinthia Bosnic-Anticevich, Gabrielle L. Onorato, M. van Eerd, S. Arnavielhe, E Mathieu-Dupas, David Price, Tari Haahtela, O. Spranger, V. Kvedariene, Claus Bachert, R Mösgues, AII - Inflammatory diseases, Ear, Nose and Throat, AII - Amsterdam institute for Infection and Immunity, Other departments, Bousquet, J, Arnavielhe, S, Bedbrook, A, Alexis-Alexandre, G, van Eerd, M, Murray, R, Canonica, G W, Illario, M, Menditto, E, Passalacqua, G, Stellato, C, Triggiani, M, Carreiro-Martins, P, Fonseca, J, Morais Almeida, M, Nogueira-Silva, L, Pereira, A M, Todo Bom, A, Bosse, I, Caimmi, D, Demoly, P, Devillier, P, Fontaine, J F, Just, J, Onorato, G L, Kowalski, M L, Kuna, P, Samolinski, B, Anto, J M, Mullol, J, Valero, A, Tomazic, P V, Bergmann, K C, Keil, T, Klimek, L, Mösgues, R, Shamai, S, Zuberbier, T, Murphy, E, Mcdowall, Peter, Price, D, Ryan, D, Sheikh, A, Chavannes, N H, Fokkens, W J, Kvedariene, V, Valiulis, A, Bachert, C, Hellings, P W, Kull, I, Melén, E, Wickman, M, Bindslev-Jensen, C, Eller, E, Haahtela, T, Valovirta, E, Papadopoulos, N G, Annesi-Maesano, I, Bewick, M, Bosnic-Anticevich, S, Cruz, A A, De Vries, G, Gemicioglu, B, Larenas-Linnemann, D, Laune, D, Mathieu-Dupas, E, O'Hehir, R E, Portejoie, F, Siroux, V, Spranger, O, Vandenplas, O, Yorgancioglu, A, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Foch [Suresnes], 'Federico II' University of Naples Medical School, CHU Montpellier, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Barcelona, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University Hospital of Cologne [Cologne], Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Vilnius University [Vilnius], Ghent University Hospital, University Hospitals Leuven [Leuven], The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], University of Helsinki, The University of Sydney, Heidelberg University, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), University of Turku, Department of Dermatology, Allergology and Venereology, Clinicum, and HUS Inflammation Center

Subjects
Research design, Male, IMPACT, Pilot Projects, Review, Global Health, law.invention, DOUBLE-BLIND, 0302 clinical medicine, FLUTICASONE, Randomized controlled trial, law, QUALITY-OF-LIFE, HDE ALER, Immunology and Allergy, Medicine, AZELASTINE, 030212 general & internal medicine, Prospective Studies, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, mHealth, Randomized Controlled Trials as Topic, treatment, Disease Management, mobile technology, observational study, rhinitis, Middle Aged, Combined Modality Therapy, Mobile Applications, 3. Good health, rhiniti, Research Design, GUIDED SELF-MANAGEMENT, [SDV.IMM]Life Sciences [q-bio]/Immunology, Over-the-counter, Female, mHealth, mobile technology, observational study, rhinitis, treatment, medicine.drug, Adult, medicine.medical_specialty, Immunology, CONTROLLED-TRIAL, Drug Prescriptions, Medication Adherence, 03 medical and health sciences, Young Adult, Quality of life (healthcare), Journal Article, Humans, Asthma, business.industry, CARE, medicine.disease, Azelastine, Rhinitis, Allergic, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, Physical therapy, ASTHMA, Observational study, business, TRADITIONAL TREATMENT
Abstract

BACKGROUND: Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology.METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries.RESULTS: A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control).CONCLUSIONS: The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved.

Published
2018

19. Work productivity in rhinitis using cell phones:The MASK pilot study

Author

Torsten Zuberbier, J. Bouchard, M. van Eerd, Giorgio Walter Canonica, Pedro Carreiro-Martins, W. J. Fokkens, Jean Bousquet, Ronald Dahl, Olivier Vandenplas, D. Laune, E Mathieu-Dupas, David Price, Tari Haahtela, O. Spranger, Joaquim Mullol, Niels H. Chavannes, B. Hellqvist-Dahl, Dermot Ryan, B. Samolinski, Josep M. Antó, K. C. Bergmann, João Fonseca, P V Tomazic, A. Todo Bom, F. Portejoie, I. Young, Sinthia Bosnic-Anticevich, Nick A. Guldemond, M. L. Kowalski, Alvaro A. Cruz, Davide Caimmi, A. Valero, M. Wickman, Erkka Valovirta, A. Fink-Wagner, A. Valiulis, Désirée Larenas-Linnemann, M. Bewick, Luís Nogueira-Silva, V. Kvedariene, Robyn E O'Hehir, Claus Bachert, Peter Hellings, L. Klimek, J. Just, G. Passalacqua, Erik Melén, T. Keil, Nikolaos G. Papadopoulos, Pascal Demoly, P. Devillier, Massimo Triggiani, R. Murray, Aziz Sheikh, G. De Vries, F. E. R. Simons, S. Arnavielhe, Carsten Bindslev-Jensen, Ana Margarida Pereira, A. Bedbrook, Piotr Kuna, M. Morais-Almeida, Public Health, Health Services Management & Organisation (HSMO), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Foch [Suresnes], Centre de l'Asthme et des Allergies [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Ear, Nose and Throat, Adult Psychiatry, AII - Inflammatory diseases, AII - Amsterdam institute for Infection and Immunity, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Trousseau [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Allergy, HEALTH-ORGANIZATION, IMPACT, Pilot Projects, Efficiency, Severity of Illness Index, App store, law.invention, Social life, 0302 clinical medicine, Randomized controlled trial, Quality of life, QUALITY-OF-LIFE, law, Surveys and Questionnaires, Medicine and Health Sciences, PERSISTENT ALLERGIC RHINITIS, Immunology and Allergy, Public Health Surveillance, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, app, Rhinitis, Work productivity, PRIMARY-CARE, work productivity, Symptom Assessment, medicine.medical_specialty, RESOURCE UTILIZATION, Visual analogue scale, Immunology, MOBILE PHONE, CONTROLLED-TRIAL, 03 medical and health sciences, rhinitis, ECONOMIC BURDEN, Severity of illness, medicine, Journal Article, Humans, Allergic Rhinitis and its Impact on Asthma, WPAIA:AS, Cell Phone, Work Performance, business.industry, ta3121, medicine.disease, 030228 respiratory system, Physical therapy, AS [WPAIA], App, business, EUROPEAN COUNTRIES
Abstract

International audience; Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to use cell phone data to assess the impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS). A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work). A combined nasal-ocular score is calculated. The Allergy Diary is available in 21 countries. The app includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) in six EU countries. All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in the study. A total of 1136 users filled in 5818 days of VAS-work. Symptoms of allergic rhinitis were controlled (VAS-global 50). There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P

Published
2017

20. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

P V Tomazic, M. Bewick, B. Samolinski, Torsten Zuberbier, Peter Hellings, M. T. Ventura, Olivier Vandenplas, Giorgio Walter Canonica, Gabrielle L. Onorato, T. Kostka, A. Todo Bom, L. Klimek, J. Just, F. Portejoie, Niels H. Chavannes, M. L. Kowalski, Bilun Gemicioglu, Ralph Mösges, Cristiana Stellato, K. C. Bergmann, T. Keil, Z. Gutter, S. Arnavielhe, David Price, Tari Haahtela, O. Spranger, Désirée Larenas-Linnemann, Massimo Triggiani, A. Yorgancioglu, Victoria Cardona, Jean-Louis Pépin, Adnan Custovic, Josep M. Antó, Nick A. Guldemond, Juan Carlos Ivancevich, B. Hellqvist-Dahl, I. Young, Robyn E O'Hehir, Benoit Pugin, H. Neffen, João O. Malva, P. Devillier, Cemal Cingi, R. Murray, J. Correia de Sousa, Erik Melén, N. Khaltaev, J. F. Fontaine, E Mathieu-Dupas, Antoine Magnan, M. Wickman, Nikolaos G. Papadopoulos, Aziz Sheikh, Leif Bjermer, G. De Vries, Edgardo Jares, F. E. R. Simons, Enrica Menditto, J. Millot-Keurinck, Sinthia Bosnic-Anticevich, Pascal Demoly, S. Palkonen, W. J. Fokkens, Jean Bousquet, S. Hun, Ronald Dahl, A. Zurkuhlen, D. Laune, A. Valero, M. Morais-Almeida, Ioana Agache, V. Kvedariene, Claus Bachert, I. Annesi-Maesano, Davide Caimmi, Milan Sova, Ana Maria Carriazo, João Fonseca, J. Bouchard, M. van Eerd, M. Barbolini, Joaquim Mullol, M. Illario, Inger Kull, Alvaro A. Cruz, E. De Manuel Keenoy, A. Bedbrook, Renaud Louis, Dermot Ryan, Piotr Kuna, Carsten Bindslev-Jensen, A. Senn, Guy Joos, Erkka Valovirta, A. Valiulis, Elaine Colgan, Paulo Augusto Moreira Camargos, G. Passalacqua, Filip Raciborski, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade de Lisboa (ULISBOA), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Service d'Allergologie pédiatrique [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Clinicum, Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, Universitat de Barcelona, Universidade do Minho, Bousquet, J., Onorato, G. L., Bachert, C., Barbolini, M., Bedbrook, A., Bjermer, L., De Sousa, J. Correia, Chavannes, N. H., Cruz, A. A., De Manuel Keenoy, E., Devillier, P., Fonseca, J., Hun, S., Kostka, T., Hellings, P. W., Illario, M., Ivancevich, J. C., Larenas-Linnemann, D., Millot-Keurinck, J., Ryan, D., Samolinski, B., Sheikh, A., Yorgancioglu, A., Agache, I., Arnavielhe, S., Bewick, M., Annesi-Maesano, I., Anto, J. M., Bergmann, K. C., Bindslev-Jensen, C., Bosnic-Anticevich, S., Bouchard, J., Caimmi, D. P., Camargos, P., Canonica, G. W., Cardona, V., Carriazo, A. M., Cingi, C., Colgan, E., Custovic, A., Dahl, R., Demoly, P., De Vries, G., Fokkens, W. J., Fontaine, J. F., Gemicioǧlu, B., Guldemond, N., Gutter, Z., Haahtela, T., Hellqvist-Dahl, B., Jares, E., Joos, G., Just, J., Khaltaev, N., Keil, T., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Laune, D., Louis, R., Magnan, A., Malva, J., Mathieu-Dupas, E., Melén, E., Menditto, E., Morais-Almeida, M., Mösges, R., Mullol, J., Murray, R., Neffen, H., O'Hehir, R., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pépin, J. L., Portejoie, F., Price, D., Pugin, B., Raciborski, F., Simons, F. E. R., Sova, M., Spranger, O., Stellato, C., Todo Bom, A., Tomazic, P. V., Triggiani, M., Valero, A., Valovirta, E., Vandenplas, O., Valiulis, A., Van Eerd, M., Ventura, M. T., Wickman, M., Young, I., Zuberbier, T., Zurkuhlen, A., Senn, A., University of Manitoba, Public Health, and Health Services Management & Organisation (HSMO)

Subjects
Pediatrics, Al·lèrgia, ARIA, Asthma, CHRODIS, Good Practices, MASK, Rhinitis, Sunfrail, Immunology and Allergy, Immunology, Pulmonary and Respiratory Medicine, Allergy, CHRONIC, [SDV]Life Sciences [q-bio], Medicina Básica [Ciências Médicas], Alternative medicine, Review, ALLIANCE, WORLD-HEALTH-ORGANIZATION, RANDOMIZED, law.invention, GLOBAL ALLIANCE, 0302 clinical medicine, Randomized controlled trial, law, QUALITY-OF-LIFE, RESPIRATORY-DISEASES, Medicine and Health Sciences, GRADING QUALITY, 030212 general & internal medicine, Rhiniti, Rinitis, media_common, Checklist, CONTROLLED-TRIALS, 3. Good health, CHRONIC RESPIRATORY-DISEASES, Ciências Médicas::Medicina Básica, CLINICAL-PRACTICE GUIDELINES, Life Sciences & Biomedicine, GLOBAL, medicine.medical_specialty, Good Practice, Visual analogue scale, RANDOMIZED CONTROLLED-TRIALS, EUROPEAN INNOVATION PARTNERSHIP, MEDLINE, GOOGLE TRENDS, 03 medical and health sciences, Quality of life (healthcare), ECONOMIC BURDEN, medicine, media_common.cataloged_instance, ddc:610, European union, Science & Technology, business.industry, RC581-607, medicine.disease, 030228 respiratory system, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, Immunologic diseases. Allergy, business
Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices., MACVIA-France., info:eu-repo/semantics/publishedVersion

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results